Gynecologic Cancers

Latest News

Graphic resembling a stamp of approval that reads "FDA Approved"
Subcutaneous Pembrolizumab Is FDA Approved, Slashes Chair Time

September 19th 2025

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median injection time of 2 minutes.

Diagram of endometrial cancer
Rx Road Map: Durvalumab for Endometrial Cancer

September 11th 2025

Line illustration of a clipboard that reads "FDA"
FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

September 10th 2025

Photo of a woman with blond hair in front of a greenery background
Opinion: Nursing Considerations for Emerging CLDN6-Targeted Therapies

September 3rd 2025

Line illustration of the female reproductive system
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer

August 26th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.